<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36934849</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-7035</ISSN><JournalIssue CitedMedium="Internet"><Volume>250</Volume><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Clinical immunology (Orlando, Fla.)</Title><ISOAbbreviation>Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS).</ArticleTitle><Pagination><StartPage>109296</StartPage><MedlinePgn>109296</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clim.2023.109296</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1521-6616(23)00075-X</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To achieve a consensus-based definition of Low Disease Activity (LDA) for use in cSLE trials.</AbstractText><AbstractText Label="METHODS">The International cSLE T2T Task Force, comprising of paediatric rheumatologists/nephrologists, and adult rheumatologists undertook a series of Delphi surveys/consensus meetings to discuss, refine, and vote upon cSLE LDA criteria.</AbstractText><AbstractText Label="RESULTS">The Task Force agreed that LDA should be based upon the adult-SLE Lupus Low Disease Activity State definition (LLDAS), with modifications to make it applicable to cSLE (cLLDAS). They agreed upon five cLLDAS criteria: (1) SLE Disease Activity Index (SLEDAI)-2&#xa0;K &#x2264;4, with no activity in major organ systems; (2) no new features of lupus disease activity compared with the last assessment; (3) Physician Global Assessment score of &#x2264;1 (0-3 scale); (4) prednisolone dose of &#x2264;0.15&#xa0;mg/kg/day, 7.5&#xa0;mg/day/maximum; while on (5) stable antimalarials, immunosuppressives, and biologics.</AbstractText><AbstractText Label="CONCLUSIONS">A cSLE-appropriate definition of cLLDAS has been generated, maintaining alignment with the adult-SLE definition to promote life-course research.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>E M D</ForeName><Initials>EMD</Initials><AffiliationInfo><Affiliation>Department of Women's &amp; Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK. Electronic address: esmith8@liverpool.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology &amp; Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ainsworth</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Women's &amp; Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Abadi</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Paediatric Rheumatology, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avcin</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Allergology, Rheumatology and Clinical Immunology, Children's Hospital, University Medical Center Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bortey</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>TARGET Lupus Public Patient Involvement and Engagement Group, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnham</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciurtin</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Adolescent Rheumatology Versus Arthritis, Division of Medicine, University College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedrich</LastName><ForeName>C M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Women's &amp; Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamphuis</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatric Rheumatology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>TARGET Lupus Public Patient Involvement and Engagement Group, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>D M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewandowski</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Lupus Genomics and Global Health Disparities Unit, Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maxwell</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>TARGET Lupus Public Patient Involvement and Engagement Group, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morand</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Inflammatory Diseases, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozen</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hacettepe University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pain</LastName><ForeName>C E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Women's &amp; Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravelli</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy; Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno Infantili (DINOGMI), Universit&#xe0; degli Studi di Genova, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad Magalhaes</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pediatric Rheumatology, Botucatu Medical School, Sao Paulo State University, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilkington</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schonenberg-Meinema</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pediatric Immunology, Rheumatology and Infectious diseases, Emma Children's Hospital, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Department of Pediatric Rheumatology, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tullus</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beresford</LastName><ForeName>M W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Women's &amp; Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>International cSLE T2T Task Force</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ARUK-20621</GrantID><Acronym>VAC_</Acronym><Agency>Versus Arthritis</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ZIA AR041214</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z99 AR999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>204822Z16Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Immunol</MedlineTA><NlmUniqueID>100883537</NlmUniqueID><ISSNLinking>1521-6616</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="Y">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Childhood-SLE</Keyword><Keyword MajorTopicYN="N">Low disease activity</Keyword><Keyword MajorTopicYN="N">T2T</Keyword><Keyword MajorTopicYN="N">Treat-to-target</Keyword><Keyword MajorTopicYN="N">cLLDAS</Keyword><Keyword MajorTopicYN="N">cSLE</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no competing interests in relation to this manuscript.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Goilav</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Albert Einstein College of Medicine, New York, USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Marks</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Great Ormond Street Hospital for Children NHS Foundation Trust and the NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Oni</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Women''s &amp; Children''s Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool UK.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>19</Day><Hour>20</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36934849</ArticleId><ArticleId IdType="mid">NIHMS1927121</ArticleId><ArticleId IdType="pmc">PMC10500564</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2023.109296</ArticleId><ArticleId IdType="pii">S1521-6616(23)00075-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED, Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus, Arthritis Rheum. 58 (2) (2008) 556&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">18240232</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, et al., Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus, Arthritis Rheum. 61 (1) (2009) 13&#x2013;20, 10.1002/art.24091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24091</ArticleId><ArticleId IdType="pmc">PMC2875186</ArticleId><ArticleId IdType="pubmed">19116979</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina R, Brunner HI, Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum. Dis. Clin. N. Am 36 (1) (2010) 53&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837537</ArticleId><ArticleId IdType="pubmed">20202591</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker LB, Uribe AG, Fernandez M, Vila LM, McGwin G, Apte M, et al., Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII), Lupus. 17 (4) (2008) 314&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818044</ArticleId><ArticleId IdType="pubmed">18413413</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al., Mortality in systemic lupus erythematosus, Arthritis Rheum. 54 (8) (2006) 2550&#x2013;2557, 10.1002/art.21955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21955</ArticleId><ArticleId IdType="pubmed">16868977</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA, et al., Differences in disease phenotype and severity in SLE across age groups, Lupus. (2016), 10.1177/0961203316644333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316644333</ArticleId><ArticleId IdType="pmc">PMC5089221</ArticleId><ArticleId IdType="pubmed">27147622</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Ideal target blood pressure in hypertension, Korean Circ J 49 (11) (2019) 1002&#x2013;1009, 10.4070/kcj.2019.0261.</Citation><ArticleIdList><ArticleId IdType="doi">10.4070/kcj.2019.0261</ArticleId><ArticleId IdType="pmc">PMC6813156</ArticleId><ArticleId IdType="pubmed">31646769</ArticleId></ArticleIdList></Reference><Reference><Citation>Swales JD, Pharmacological treatment of hypertension, Lancet. 344 (8919) (1994) 380&#x2013;385, 10.1016/s0140-6736(94)91405-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(94)91405-2</ArticleId><ArticleId IdType="pubmed">7914311</ArticleId></ArticleIdList></Reference><Reference><Citation>Eastman RC, Keen H, The impact of cardiovascular disease on people with diabetes: the potential for prevention, Lancet. 350 (Suppl. 1) (1997) SI29&#x2013;32, 10.1016/s0140-6736(97)90026-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(97)90026-x</ArticleId><ArticleId IdType="pubmed">9250281</ArticleId></ArticleIdList></Reference><Reference><Citation>Wangnoo SK, Sethi B, Sahay RK, John M, Ghosal S, Sharma SK, Treat-to-target trials in diabetes, Indian J. Endocrinol. Metab 18 (2) (2014) 166&#x2013;174, 10.4103/2230-8210.129106.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2230-8210.129106</ArticleId><ArticleId IdType="pmc">PMC3987265</ArticleId><ArticleId IdType="pubmed">24741511</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O&#x2019;Dwyer JL, et al., Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial, Lancet. 386 (10012) (2015) 2489&#x2013;2498, 10.1016/s0140-6736(15)00347-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(15)00347-5</ArticleId><ArticleId IdType="pmc">PMC4920221</ArticleId><ArticleId IdType="pubmed">26433318</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EMD, Tharmaratnam K, Al-Abadi E, Armon K, Bailey K, Brennan M, et al., Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus, Rheumatology (Oxford) (2021), 10.1093/rheumatology/keab915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab915</ArticleId><ArticleId IdType="pmc">PMC9348762</ArticleId><ArticleId IdType="pubmed">34894234</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EMD, Gorst SL, Al-Abadi E, Hawley DP, Leone V, Pilkington C, et al., &#x201c;It is good to have a target in mind&#x201d;: qualitative views of patients and parents informing a treat to target clinical trial in JSLE, Rheumatology (Oxford) (2021), 10.1093/rheumatology/keab173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab173</ArticleId><ArticleId IdType="pmc">PMC8645274</ArticleId><ArticleId IdType="pubmed">33629109</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahadat MJ, van den Berg L, Timmermans D, van Rijswijk K, van Dijk-Hummelman A, Bakx S, et al., LLDAS is an attainable treat-to-target goal in childhood-onset SLE, Lupus Sci. Med 8 (1) (2021), 10.1136/lupus-2021-000571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000571</ArticleId><ArticleId IdType="pmc">PMC8719245</ArticleId><ArticleId IdType="pubmed">34969874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozturk K, Caglayan S, Tanatar A, Baglan E, Yener Otar G, Kavrul Kayaalp G, et al., Low disease activity state in juvenile-onset systemic lupus erythematosus, Lupus. 30 (13) (2021) 2144&#x2013;2150, 10.1177/09612033211054399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211054399</ArticleId><ArticleId IdType="pubmed">34723709</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott RS, Taylor E, Ainsworth J, Preston J, Smith E, Improving communication of the concept of &#x2018;treat-to target&#x2019; in childhood lupus: a public and patient (PPI) engagement project involving children and young people, BMC Rheumatol 6 (1) (2022) 69, 10.1186/s41927-022-00300-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41927-022-00300-z</ArticleId><ArticleId IdType="pmc">PMC9578343</ArticleId><ArticleId IdType="pubmed">36242078</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EMD, Egbivwie N, Cowan K, Ramanan AV, Pain CE, Research priority setting for paediatric rheumatology in the UK, Lancet Rheumatol. 4 (7) (2022), 10.1016/S2665-9913(22)00106-0 e517&#x2013;e24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00106-0</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, et al., A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS), Ann. Rheum. Dis 76 (3) (2017) 554&#x2013;561, 10.1136/annrheumdis-2016-209519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209519</ArticleId><ArticleId IdType="pubmed">27884822</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al., Treat-to-target in systemic lupus erythematosus: recommendations from an international task force, Ann. Rheum. Dis 73 (6) (2014) 958&#x2013;967, 10.1136/annrheumdis-2013-205139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205139</ArticleId><ArticleId IdType="pubmed">24739325</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA, et al., DORIS definition of remission in SLE: final recommendations from an international task force, Lupus Sci. Med 8 (1) (2021), 10.1136/lupus-2021-000538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000538</ArticleId><ArticleId IdType="pmc">PMC8614136</ArticleId><ArticleId IdType="pubmed">34819388</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Kandane-Rathnayake R, Huq M, Nim HT, Louthrenoo W, Luo SF, et al., Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study, Lancet Rheumatol. 1 (2) (2019) e95&#x2013;e102, 10.1016/S2665-9913(19)30037-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30037-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Kandane-Rathnayake R, Huq M, Louthrenoo W, Luo SF, Wu Y-JJ, et al., Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study, Lancet. Rheumatol 1 (2) (2019), 10.1016/S2665-9913(19)30048-7 e103&#x2013;e10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30048-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al., Definition and initial validation of a lupus low disease activity state (LLDAS), Ann. Rheum. Dis 75 (9) (2016) 1615&#x2013;1621, 10.1136/annrheumdis-2015-207726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolopoulos D, Kandane-Rathnayake R, Louthrenoo W, Luo SF, Wu Y-J, Lateef A, et al., Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study, Lancet Rheumatol. 2 (1) (2020) e24&#x2013;e30, 10.1016/S2665-9913(19)30105-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30105-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, et al., Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study, Semin. Arthritis Rheum 48 (3) (2018) 467&#x2013;474, 10.1016/j.semarthrit.2018.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2018.02.014</ArticleId><ArticleId IdType="pubmed">29555348</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Magder LS, Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort, Arthritis Rheum. 70 (11) (2018) 1790&#x2013;1795, 10.1002/art.40571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40571</ArticleId><ArticleId IdType="pmc">PMC6203602</ArticleId><ArticleId IdType="pubmed">29806142</ArticleId></ArticleIdList></Reference><Reference><Citation>Piga M, Floris A, Cappellazzo G, Chessa E, Congia M, Mathieu A, et al., Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus, Arthritis Res. Ther 19 (1) (2017) 247, 10.1186/s13075-017-1451-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1451-5</ArticleId><ArticleId IdType="pmc">PMC5681839</ArticleId><ArticleId IdType="pubmed">29126432</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani C, Vagelli R, Stagnaro C, Carli L, Mosca M, Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort, Lupus Sci. Med 5 (1) (2018), e000234, 10.1136/lupus-2017-000234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2017-000234</ArticleId><ArticleId IdType="pmc">PMC5844382</ArticleId><ArticleId IdType="pubmed">29531772</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang-A-Sjoe MWP, Bultink IEM, Heslinga M, Voskuyl AE, Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus, Rheumatology (Oxford) 56 (1) (2016) 121&#x2013;128, 10.1093/rheumatology/kew377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew377</ArticleId><ArticleId IdType="pubmed">27803306</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Pons-Estel GJ, Vila LM, McGwin G, Alarc&#xf3;n GS, Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort, RMD Open. 5 (1) (2019), e000955, 10.1136/rmdopen-2019-000955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2019-000955</ArticleId><ArticleId IdType="pmc">PMC6560976</ArticleId><ArticleId IdType="pubmed">31245057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Catoggio LJ, Drenkard C, Sarano J, et al., Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American lupus cohort (GLADEL), Ann. Rheum. Dis 76 (12) (2017) 2071&#x2013;2074, 10.1136/annrheumdis-2017-211814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211814</ArticleId><ArticleId IdType="pubmed">28939626</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo AL, Koelmeyer R, Kandane-Rathnayake R, Golder V, Hoi A, Huq M, et al., Lupus low disease activity state and reduced direct health care costs in patients with systemic lupus erythematosus, Arthritis Care Res. 72 (9) (2020) 1289&#x2013;1295, 10.1002/acr.24023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24023</ArticleId><ArticleId IdType="pubmed">31282076</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra Sanchez AR, Voskuyl AE, van Vollenhoven RF, Treat-to-target in systemic lupus erythematosus: advancing towards its implementation, Nat. Rev. Rheumatol 18 (3) (2022) 146&#x2013;157, 10.1038/s41584-021-00739-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00739-3</ArticleId><ArticleId IdType="pubmed">35039665</ArticleId></ArticleIdList></Reference><Reference><Citation>Zen M, Iaccarino L, Gatto M, Saccon F, Larosa M, Ghirardello A, et al., Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission, Ann. Rheum. Dis 77 (1) (2018) 104&#x2013;110, 10.1136/annrheumdis-2017-211613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211613</ArticleId><ArticleId IdType="pubmed">28970217</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen Y-H, Cho J, Lateef A, et al., Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study, Lancet Rheumatol. 4 (12) (2022), 10.1016/S2665-9913(22)00304-6 e822&#x2013;e30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00304-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EMD, Aggarwal A, Ainsworth J, Al-Abadi E, Avcin T, Bortey L, et al., Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force, Ann. Rheum. Dis (2022), 10.1136/ard-2022-223328. Published Online First: 10 January 2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-223328</ArticleId><ArticleId IdType="pmc">PMC10314055</ArticleId><ArticleId IdType="pubmed">36627168</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantrill JA, Sibbald B, Buetow S, The Delphi and nominal group techniques in health services research, Int. J. Pharm. Pract 4 (2) (1996) 67&#x2013;74, doi: 1111/j.2042&#x2013;7174.1996.tb00844.x.</Citation></Reference><Reference><Citation>Ko K L A, Griffin R, Dvorkina O, Sheikh S, Yazdany J, Furie R, Aranow C, Baseline predictors of remission and low disease activity using recently defined international criteria in a multi-center lupus registry cohort (abstract), Arthritis Rheum. 67 (Suppl. 10) (2015).</Citation></Reference><Reference><Citation>Polachek A, Gladman DD, Su J, Urowitz MB, Defining low disease activity in systemic lupus erythematosus, Arthritis Care Res. 69 (7) (2017) 997&#x2013;1003, 10.1002/acr.23109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23109</ArticleId><ArticleId IdType="pubmed">27696791</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE, Arthritis Rheum. 35 (6) (1992) 630&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">1599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Piga M, Chessa E, Morand EF, Ugarte-Gil MF, Tektonidou M, van Vollenhoven R, et al., Physician global assessment international standardisation COnsensus in systemic lupus erythematosus: the PISCOS study, Lancet Rheumatol. 4 (6) (2022), 10.1016/S2665-9913(22)00107-2 e441&#x2013;e9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00107-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Chessa E, Piga M, Floris A, Devilliers H, Cauli A, Arnaud L, Use of physician global assessment in systemic lupus erythematosus: a systematic review of its psychometric properties, Rheumatology (Oxford) 59 (12) (2020) 3622&#x2013;3632, 10.1093/rheumatology/keaa383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa383</ArticleId><ArticleId IdType="pubmed">32789462</ArticleId></ArticleIdList></Reference><Reference><Citation>Thamer M, Hernan MA, Zhang Y, Cotter D, Petri M, Prednisone, lupus activity, and permanent organ damage, J. Rheumatol 36 (3) (2009) 560&#x2013;564, 10.3899/jrheum.080828.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.080828</ArticleId><ArticleId IdType="pmc">PMC3624968</ArticleId><ArticleId IdType="pubmed">19208608</ArticleId></ArticleIdList></Reference><Reference><Citation>Heshin-Bekenstein M, Trupin L, Yelin E, von Scheven E, Yazdany J, Lawson EF, Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus, Semin. Arthritis Rheum 49 (2) (2019) 267&#x2013;272, 10.1016/j.semarthrit.2019.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.05.010</ArticleId><ArticleId IdType="pmc">PMC7480934</ArticleId><ArticleId IdType="pubmed">31235075</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al., Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial, Lancet. 364 (9430) (2004) 263&#x2013;269, 10.1016/S0140-6736(04)16676-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)16676-2</ArticleId><ArticleId IdType="pubmed">15262104</ArticleId></ArticleIdList></Reference><Reference><Citation>Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, van den Bosch WB, Koopman-Keemink Y, Brederije ICJ, et al., Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial, Ann. Rheum. Dis 78 (1) (2019) 51&#x2013;59, 10.1136/annrheumdis-2018-213902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213902</ArticleId><ArticleId IdType="pubmed">30309970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, et al., Treatment to target using recombinant Interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study, Arthritis Rheum. 71 (7) (2019) 1163&#x2013;1173, 10.1002/art.40865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40865</ArticleId><ArticleId IdType="pmc">PMC6617757</ArticleId><ArticleId IdType="pubmed">30848528</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>